Preclinically, several studies have demonstrated that both AKT and PI3K inhibitors have single-agent activity across prostate cancer cell lines and tumor xenograft models with PTEN loss (Hancox et al., 2015; Marques et al., 2015). This evidence concerns the gene AKT1 and prostate carcinoma.